Drug intelligence / Profile preview

pHIS-HIV-AE

Development stage: Phase 2
Lead developer: The Kirby Institute
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

pHIS-HIV-AE is an experimental DNA vaccine candidate developed by the Kirby Institute for the prevention of HIV-1 infection, specifically targeting the AE clade (subtype) prevalent in Southeast Asia. The vaccine utilizes a DNA vector to deliver HIV-1 genes, intended to prime the immune system as part of a heterologous prime-boost strategy. In clinical evaluation, it was administered alongside a recombinant fowlpox virus boost (rFPV-HIV-AE) expressing matching antigens. A Phase I/II trial (NCT00333424) in healthy Thai volunteers was initiated to evaluate safety and immunogenicity but was subsequently terminated.

Other names: pHIS-HIV-AE DNA vaccine

Targets

HIV-1 CRF01_AE antigens

Beyond the preview

Go deeper on pHIS-HIV-AE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pHIS-HIV-AE.

Explore the full profile